XTLB 주가 차트
XTLB 수입
XTL Biopharmaceuticals Ltd.
$2.51
-1.18%
$-0.03
종가: May 22, 16:00:00 GMT-4
$2.6
3.58%
$0.09
애프터마켓: May 22, 20:00:00 GMT-4
뒤로
XTL Biopharmaceuticals Ltd. (XTLB) 수입
Earnings FAQ
XTLB의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
XTL Biopharmaceuticals Ltd. XTLB의 지난 분기 매출 실적은 어땠나요?
XTL Biopharmaceuticals Ltd.의 매출 추정치는 얼마인가요?
XTL Biopharmaceuticals Ltd.의 수익 품질 점수는 얼마인가요?
XTL Biopharmaceuticals Ltd.는 언제 수익을 보고하나요?
XTL Biopharmaceuticals Ltd.의 예상 수익은 얼마인가요?
XTL Biopharmaceuticals Ltd.은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$2.54
시가
$2.5
일일 범위
$2.46 - $2.64
52주 범위
$2.12 - $10.28
거래량
37.7K
평균 거래량
1.9M
배당수익률
--
EPS(TTM)
-3.60
시가총액
$6.1M
XTL Biopharmaceuticals Ltd.란 무엇인가요?
XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. The firm pipelines include hCDR1 systematic lupus erythematosus and recombinant human erythropoietin (rHuEPO) multiple myeloma. Its hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS). hCDR1 is a peptide that is administered subcutaneously and acts as a disease-specific treatment to modify the SLE-related autoimmune process. The rHuEPO known agent for anemia to prolong a survival of patients for treatment of multiple myeloma blood cancer. Its Erythropoietin (EPO) is a glycoprotein hormone produced mainly by kidneys. EPO stimulates erythropoiesis, production of red blood cells, by binding to its receptor on a surface of erythroid progenitor cells, promoting their proliferation and differentiation and maintaining their viability.
